Maverick Life

Tekmira Ebola drug gets regulator change for possible human use

By Reuters 7 August 2014

Tekmira Pharmaceutical Corp said on Thursday that the U.S. Food and Drug Administration had modified its clinical hold status on Tekmira's experimental Ebola treatment to enable its potential use in humans infected with the virus. By Rod Nickel for Reuters.

The FDA told Burnaby, British Columbia-based Tekmira that it had modified the full clinical hold on the drug to a partial clinical hold, the company said in a statement.

“We are pleased that the FDA has considered the risk-reward of TKM-Ebola for infected patients,” said Dr. Mark Murray, Tekmira’s chief executive officer. “We have been closely watching the Ebola virus outbreak and its consequences, and we are willing to assist with any responsible use of TKM-Ebola.”

The recent Ebola outbreak has killed nearly 1,000 people in West Africa.

The World Health Organization (WHO) on Wednesday said it would convene a meeting of medical ethics experts next week to consider the implications of making experimental Ebola drugs more widely available.

Tekmira’s Ebola treatment is one of three worldwide that have shown especially promising results in monkeys, but it is unproven in humans.

Tiny California biotech Mapp Biopharmaceutical gained international prominence this week when its drug was given to two U.S. aid workers who contracted Ebola in West Africa and have since shown signs of improvement.

Shares of Burnaby, British Columbia-based Tekmira surged 40 percent last week as the worst-ever outbreak of the Ebola virus intensified. The buying spree came even as human tests of Tekmira’s treatment, TKM-Ebola, were put on hold last month.

Tekmira’s drug has only been tested in a few dozen healthy people. The FDA stopped its study in July because of safety concerns among people taking the highest doses of the drug who experienced problematic immune responses.

The hold meant that that particular study cannot proceed, but it does not prevent the company from submitting a new study proposal, say in people already infected with Ebola, for whom any safety risks from the treatment would be mitigated by the risk of dying.

In that case, “the benefit-risk ratio changes completely,” a source within the FDA told Reuters last week. “Anything that would shift the risk-benefit to a more favorable outcome could potentially allow the authorization of that study.”

In that case, the source said, a company would have a partial clinical hold in which the original study in healthy patients remained on hold and the new study in sick patients could proceed.

Tekmira stock finished trading on Thursday in Toronto up 6.6 percent at C$15.61, after a late rally prior to a trading halt pending the news. DM

Photo: A handout photo released by the Spanish Defense Ministry shows several paramedics wearing protective suits as they mov Spanish missionary Miguel Pajares, who is infected with ebola, into an ambulance upon his arrival at Spanish Air Force base in Torrejon de Ardoz, outside Madrid, Spain, 07 August 2014. Pajares and missionary Juliana Bohi, who is not infected, were moved to Carlos III Hospital, in Madrid, to be treated after they arrived from Liberia on board a Spanish Air Force plane. EPA/SPANISH DEFENSE MINISTRY / HANDOUT

Gallery

Are You A South AfriCAN or a South AfriCAN'T?

Maverick Insider is more than a reader revenue scheme. While not quite a "state of mind", it is a mindset: it's about believing that independent journalism makes a genuine difference to our country and it's about having the will to support that endeavour.

From the #GuptaLeaks into State Capture to the Scorpio exposés into SARS, Daily Maverick investigations have made an enormous impact on South Africa and it's political landscape. As we enter an election year, our mission to Defend Truth has never been more important. A free press is one of the essential lines of defence against election fraud; without it, national polls can turn very nasty, very quickly as we have seen recently in the Congo.

If you would like a practical, tangible way to make a difference in South Africa consider signing up to become a Maverick Insider. You choose how much to contribute and how often (monthly or annually) and in exchange, you will receive a host of awesome benefits. The greatest benefit of all (besides inner peace)? Making a real difference to a country that needs your support.


Comments

Please or create an account to view the comments. To join the conversation, sign up as a Maverick Insider.

SCORPIO

Exclusive: Batohi acts fast, tough in Bosasa’s NPA mole case

By Jessica Bezuidenhout

Female-named hurricanes kill more people on average than male hurricanes. This is due to people not being as intimidated by the former as the latter.